stockrowMyriad Genetics, Inc. (MYGN) vs GeneDx Holdings Corp. (WGS)
- Myriad Genetics, Inc. MYGN 6.19 +2.82%
- GeneDx Holdings Corp. WGS 64.89 −6.42%
Myriad Genetics, Inc. and GeneDx Holdings Corp. are both Diagnostics & Research companies. GeneDx Holdings Corp. is the larger, with a market value of $1.9B against $601.6M — 3.2× the size. GeneDx Holdings Corp. grew revenue faster over the last twelve months: 25.4% against −3.16%. Myriad Genetics, Inc. has the higher net margin (−14.0% vs −23.4%) and the higher return on invested capital (−19.9% vs −27.7%). Across the 18 metrics below, Myriad Genetics, Inc. leads on 10 and GeneDx Holdings Corp. on 8.
Valuation
Profitability
| Metric | MYGN | WGS | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 68.83% | 69.37% | 48.32% |
| Operating margin | (12.22%) | (20.34%) | (5.68%) |
| Net margin | (13.96%) | (23.40%) | (4.10%) |
| Free cash flow margin | (1.76%) | (16.68%) | 0.00% |
| Return on equity | (32.54%) | (40.80%) | 0.00% |
| Return on assets | (17.11%) | (22.50%) | (6.05%) |
| Return on invested capital | (19.92%) | (27.70%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack